Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Message from the Chairmen.

Clinical lymphoma, myeloma & leukemia

Lonial S, Kantarjian H, Freireich EJ.
PMID: 32862847
Clin Lymphoma Myeloma Leuk. 2020 Sep;20:S1. doi: 10.1016/S2152-2650(20)30439-0.

No abstract available.

Cite
Lonial S, Kantarjian H, Freireich EJ. Message from the Chairmen. Clin Lymphoma Myeloma Leuk. 2020;20:S1doi: 10.1016/S2152-2650(20)30439-0.
Lonial, S., Kantarjian, H., & Freireich, E. J. (2020). Message from the Chairmen. Clinical lymphoma, myeloma & leukemia, 20S1. https://doi.org/10.1016/S2152-2650(20)30439-0
Lonial, Sagar, et al. "Message from the Chairmen." Clinical lymphoma, myeloma & leukemia vol. 20 (2020): S1. doi: https://doi.org/10.1016/S2152-2650(20)30439-0
Lonial S, Kantarjian H, Freireich EJ. Message from the Chairmen. Clin Lymphoma Myeloma Leuk. 2020 Sep;20:S1. doi: 10.1016/S2152-2650(20)30439-0. PMID: 32862847.
Copy Download .nbib Format: NLM
The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.

Frontiers in oncology

Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F.
PMID: 24032106
Front Oncol. 2013 Sep 06;3:218. doi: 10.3389/fonc.2013.00218. eCollection 2013.

BACKGROUND: Previous studies have suggested that NPM1 mutations may be a marker for response to all-trans retinoic acid (ATRA) given as an adjunct to intensive chemotherapy in older patients with acute myeloid leukemia (AML).PATIENTS AND METHODS: We examined the...

Cite
Nazha A, Bueso-Ramos C, Estey E, et al. The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Front Oncol. 2013;3:218doi: 10.3389/fonc.2013.00218.
Nazha, A., Bueso-Ramos, C., Estey, E., Faderl, S., O'Brien, S., Fernandez, M. H., Nguyen, M., Koller, C., Freireich, E., Beran, M., Pierce, S., Keating, M., Cortes, J., Kantarjian, H., & Ravandi, F. (2013). The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Frontiers in oncology, 3218. https://doi.org/10.3389/fonc.2013.00218
Nazha, Aziz, et al. "The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia." Frontiers in oncology vol. 3 (2013): 218. doi: https://doi.org/10.3389/fonc.2013.00218
Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F. The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Front Oncol. 2013 Sep 06;3:218. doi: 10.3389/fonc.2013.00218. eCollection 2013. PMID: 24032106; PMCID: PMC3764477.
Copy Download .nbib Format: NLM
The road to cancer control goes through leukemia research.

Current oncology (Toronto, Ont.)

Freireich EJ.
PMID: 19862355
Curr Oncol. 2009 Sep;16(5):1-2. doi: 10.3747/co.v16i5.480.

No abstract available.

Cite
Freireich EJ. The road to cancer control goes through leukemia research. Curr Oncol. 2009;16(5):1-2doi: 10.3747/co.v16i5.480.
Freireich, E. J. (2009). The road to cancer control goes through leukemia research. Current oncology (Toronto, Ont.), 16(5), 1-2. https://doi.org/10.3747/co.v16i5.480
Freireich, E J. "The road to cancer control goes through leukemia research." Current oncology (Toronto, Ont.) vol. 16,5 (2009): 1-2. doi: https://doi.org/10.3747/co.v16i5.480
Freireich EJ. The road to cancer control goes through leukemia research. Curr Oncol. 2009 Sep;16(5):1-2. doi: 10.3747/co.v16i5.480. PMID: 19862355; PMCID: PMC2768504.
Copy Download .nbib Format: NLM
Hydrogen Sulfide Poisoning: Report of Two Cases, One with Fatal Outcome, from Associated Mechanical Asphyxia.

The American journal of pathology

Freireich AW.
PMID: 19970859
Am J Pathol. 1946 Jan;22(1):147-55.

No abstract available.

Cite
Freireich AW. Hydrogen Sulfide Poisoning: Report of Two Cases, One with Fatal Outcome, from Associated Mechanical Asphyxia. Am J Pathol. 1946;22(1):147-55
Freireich, A. W. (1946). Hydrogen Sulfide Poisoning: Report of Two Cases, One with Fatal Outcome, from Associated Mechanical Asphyxia. The American journal of pathology, 22(1), 147-55.
Freireich, A W. "Hydrogen Sulfide Poisoning: Report of Two Cases, One with Fatal Outcome, from Associated Mechanical Asphyxia." The American journal of pathology vol. 22,1 (1946): 147-55.
Freireich AW. Hydrogen Sulfide Poisoning: Report of Two Cases, One with Fatal Outcome, from Associated Mechanical Asphyxia. Am J Pathol. 1946 Jan;22(1):147-55. PMID: 19970859; PMCID: PMC1934159.
Copy Download .nbib Format: NLM
The african organization for research and training in cancer.

Current oncology (Toronto, Ont.)

Freireich EJ.
PMID: 23144570
Curr Oncol. 2012 Oct;19(5):245. doi: 10.3747/co.19.1102.

No abstract available.

Cite
Freireich EJ. The african organization for research and training in cancer. Curr Oncol. 2012;19(5):245doi: 10.3747/co.19.1102.
Freireich, E. J. (2012). The african organization for research and training in cancer. Current oncology (Toronto, Ont.), 19(5), 245. https://doi.org/10.3747/co.19.1102
Freireich, E J. "The african organization for research and training in cancer." Current oncology (Toronto, Ont.) vol. 19,5 (2012): 245. doi: https://doi.org/10.3747/co.19.1102
Freireich EJ. The african organization for research and training in cancer. Curr Oncol. 2012 Oct;19(5):245. doi: 10.3747/co.19.1102. PMID: 23144570; PMCID: PMC3457873.
Copy Download .nbib Format: NLM
Droplet-based characterization of surfactant efficacy in colloidal stabilization of carbon black in nonpolar solvents.

Journal of colloid and interface science

Bleier BJ, Yezer BA, Freireich BJ, Anna SL, Walker LM.
PMID: 28110061
J Colloid Interface Sci. 2017 May 01;493:265-274. doi: 10.1016/j.jcis.2017.01.033. Epub 2017 Jan 10.

Development of an electrostatic stabilization mechanism for colloidal suspensions in nonpolar fluids requires an improved understanding of the interactions between the inverse micelles and particles as well as the roles that steric and electrostatic effects play. A droplet-based millifluidic...

Cite
Bleier BJ, Yezer BA, Freireich BJ, et al. Droplet-based characterization of surfactant efficacy in colloidal stabilization of carbon black in nonpolar solvents. J Colloid Interface Sci. 2017;493:265-274doi: 10.1016/j.jcis.2017.01.033.
Bleier, B. J., Yezer, B. A., Freireich, B. J., Anna, S. L., & Walker, L. M. (2017). Droplet-based characterization of surfactant efficacy in colloidal stabilization of carbon black in nonpolar solvents. Journal of colloid and interface science, 493265-274. https://doi.org/10.1016/j.jcis.2017.01.033
Bleier, Blake J, et al. "Droplet-based characterization of surfactant efficacy in colloidal stabilization of carbon black in nonpolar solvents." Journal of colloid and interface science vol. 493 (2017): 265-274. doi: https://doi.org/10.1016/j.jcis.2017.01.033
Bleier BJ, Yezer BA, Freireich BJ, Anna SL, Walker LM. Droplet-based characterization of surfactant efficacy in colloidal stabilization of carbon black in nonpolar solvents. J Colloid Interface Sci. 2017 May 01;493:265-274. doi: 10.1016/j.jcis.2017.01.033. Epub 2017 Jan 10. PMID: 28110061.
Copy Download .nbib Format: NLM
Ethical issues in clinical trials.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Freireich EJ.
PMID: 3179398
Biomed Pharmacother. 1988;42(3):157-8.

No abstract available.

Cite
Freireich EJ. Ethical issues in clinical trials. Biomed Pharmacother. 1988;42(3):157-8
Freireich, E. J. (1988). Ethical issues in clinical trials. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 42(3), 157-8.
Freireich, E J. "Ethical issues in clinical trials." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 42,3 (1988): 157-8.
Freireich EJ. Ethical issues in clinical trials. Biomed Pharmacother. 1988;42(3):157-8. PMID: 3179398.
Copy Download .nbib Format: NLM
Lesson on leukemia.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Freireich EJ.
PMID: 17577253
J BUON. 2002 Jan-Mar;7(1):9-11.

No abstract available.

Cite
Freireich EJ. Lesson on leukemia. J BUON. 2002;7(1):9-11
Freireich, E. J. (2002). Lesson on leukemia. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 7(1), 9-11.
Freireich, E J. "Lesson on leukemia." Journal of B.U.ON. : official journal of the Balkan Union of Oncology vol. 7,1 (2002): 9-11.
Freireich EJ. Lesson on leukemia. J BUON. 2002 Jan-Mar;7(1):9-11. PMID: 17577253.
Copy Download .nbib Format: NLM
Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver).

The Lancet. Oncology

Freireich EJ.
PMID: 11905728
Lancet Oncol. 2001 Aug;2(8):514-9. doi: 10.1016/s1470-2045(01)00458-2.

No abstract available.

Cite
Freireich EJ. Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver). Lancet Oncol. 2001;2(8):514-9doi: 10.1016/s1470-2045(01)00458-2.
Freireich, E. J. (2001). Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver). The Lancet. Oncology, 2(8), 514-9. https://doi.org/10.1016/s1470-2045(01)00458-2
Freireich, E J. "Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver)." The Lancet. Oncology vol. 2,8 (2001): 514-9. doi: https://doi.org/10.1016/s1470-2045(01)00458-2
Freireich EJ. Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver). Lancet Oncol. 2001 Aug;2(8):514-9. doi: 10.1016/s1470-2045(01)00458-2. PMID: 11905728.
Copy Download .nbib Format: NLM
Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia.

Leukemia & lymphoma

Keating MJ, Hester JP, McCredie KB, Burgess MA, Murphy WK, Freireich EJ.
PMID: 27457043
Leuk Lymphoma. 1990;2(6):391-7. doi: 10.3109/10428199009069292.

This study was designed to study the efficacy and toxicity of an adriamycin-containing regimen (CAP: cyclophosphamide, adriamycin, and prednisone) in patients with previously untreated chronic lymphocytic leukemia (CLL). CAP was given to clinical complete remission followed by 18 months...

Cite
Keating MJ, Hester JP, McCredie KB, et al. Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia. Leuk Lymphoma. 1990;2(6):391-7doi: 10.3109/10428199009069292.
Keating, M. J., Hester, J. P., McCredie, K. B., Burgess, M. A., Murphy, W. K., & Freireich, E. J. (1990). Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia. Leukemia & lymphoma, 2(6), 391-7. https://doi.org/10.3109/10428199009069292
Keating, M J, et al. "Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia." Leukemia & lymphoma vol. 2,6 (1990): 391-7. doi: https://doi.org/10.3109/10428199009069292
Keating MJ, Hester JP, McCredie KB, Burgess MA, Murphy WK, Freireich EJ. Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia. Leuk Lymphoma. 1990;2(6):391-7. doi: 10.3109/10428199009069292. PMID: 27457043.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries